---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288751045.md"
description: "Veru sharews are trading higher after the company announced it entered into a clinical supply agreement with Novo Nordisk to evaluate the combination of Enobosarm with Wegovy."
datetime: "2026-06-04T16:16:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288751045.md)
  - [en](https://longbridge.com/en/news/288751045.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288751045.md)
generator: "portal-rs"
---

# 

Veru sharews are trading higher after the company announced it entered into a clinical supply agreement with Novo Nordisk to evaluate the combination of Enobosarm with Wegovy.

### Related Stocks

- [VERU.US](https://longbridge.com/en/quote/VERU.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Novo Nordisk halts two trials testing ziltivekimab, Bloomberg reports](https://longbridge.com/en/news/298257409.md)
- [Veru CEO Steiner to join Cantor Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297786525.md)
- [Novo Nordisk: Late-stage Trial Shows Semaglutide Can Improve Childhood Obesity Rate](https://longbridge.com/en/news/298247968.md)
- [Novo scraps two more heart drug trials, further dimming growth beyond obesity](https://longbridge.com/en/news/298210952.md)
- [Veru wins US patent allowance for enobosarm-semaglutide weight-loss regimen claims](https://longbridge.com/en/news/294825380.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**